StockData

Prestige Consumer Healthcare vs USANA Health Sciences

PBH and USNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PBH and USNA compare

Prestige Consumer Healthcare is the larger company, worth 9.1 times as much as USANA Health Sciences ($2.3B against $251M).

USANA Health Sciences grew revenue faster over the last twelve months (1.6% versus −1.4% for Prestige Consumer Healthcare).

Prestige Consumer Healthcare keeps more of each dollar of sales as profit, with a net margin of 15.6% compared with −2.4% at USANA Health Sciences.

Prestige Consumer Healthcare scores higher on the StockData Score (12 against 11 for USANA Health Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPBHUSNA
Size and price
Market cap$2.3B$251M
Share price$48.22$13.57
Change, 1 year−19.6%−29.3%
Change, 5 years−14.5%−86.4%
Beta (5Y)0.740.06
Employees8901,570
StockData Score
Total score12 (better)11
Valuation score5 (better)4
Growth score1 (better)0
Performance score4 (better)2
Health score25 (better)
Dividend score00
Valuation
P/E13.5×–
P/S2.1×0.3× (better)
P/B1.2×0.5× (better)
EV/EBITDA13.1×2.6× (better)
P/FCF9.7× (better)15.7×
FCF yield10.3% (better)6.4%
Fair value$63.54$32.40
Margin of safety24.1%58.1% (better)
Growth
Revenue growth (TTM)−1.4%1.6% (better)
Revenue growth, 5Y average2.9% (better)−4.0%
Net income growth (TTM)−19.2% (better)−165%
EPS growth (TTM)−16.2% (better)−167%
EPS growth, 5Y average3.8% (better)−37.0%
Profitability
Gross margin53.5%77.4% (better)
Operating margin26.3% (better)−0.12%
Net margin15.6% (better)−2.4%
FCF margin21.3% (better)1.7%
Return on equity9.1% (better)−4.2%
Return on invested capital8.2% (better)−0.15%
Financial health
Debt / equity1.05 (better)0.00
Net debt / EBITDA5.98–
Interest coverage–−2.6×
Current ratio3.23 (better)2.66
Altman Z-score1.603.63 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Buyback yield5.3% (better)0.00%
Shareholder yield5.3% (better)0.00%
Ownership
Held by institutions113%66.2%
Held by insiders1.4%40.9%
Insider net buying, 12 months−$203K (better)−$895K
Short interest, % of float9.1%8.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.